股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 醫思健康 | | | | | | 呈交日期: | 2026年2月4日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02138 | 說明 | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 38,000,000,000 | HKD | 0.00001 | HKD | | 380,000 | | 增加 / 減少 (-) | | | | | HKD | | | | 本月底結存 | | 3 ...

医思健康是一家主要从事提供医疗及保健服务的投资控股公司。该公司主要通过三个业务分部进行运 营。医疗服务分部提供医疗服务及牙科服务等。美学医疗、美容及养生服务分部提供美学医疗、传统美 容、护发及辅助养生服务以及销售护肤、保健及美容产品。其他分部提供营销及相关服务以及兽医服 务。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-02 | 2004.90万 | -2.10万 | -0.10% | | 2026-01-21 | 2007.00万 | -6.50万 | -0.32% | | 2026-01-15 | 2013.50万 | -1000.0 | -0.00% | | 2026-01-14 | 2013.60万 | -1.10万 | -0.05% | | 2026-01-13 | 2014.70万 | -4.70万 | -0.23% | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月2日南向资金减持2.1万股医思健康（0 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Meisi Health (02138.HK) by 39,000 shares on January 8, indicating a trend of net selling over recent trading days [1] - Over the past five trading days, southbound funds have reduced their holdings for five consecutive days, totaling a net reduction of 483,000 shares [1] - In the last twenty trading days, there has been a consistent reduction in holdings by southbound funds, with a cumulative net reduction of 1,185,000 shares [1] Group 2 - As of now, southbound funds hold 19.4 million shares of Meisi Health (02138.HK), which represents 1.7% of the company's total issued ordinary shares [1] - Meisi Health operates primarily as an investment holding company providing medical and healthcare services through three business segments [1] - The medical services segment offers medical and dental services, while the aesthetic medical, beauty, and wellness services segment provides aesthetic medical, traditional beauty, hair care, and wellness services, along with the sale of skincare, health, and beauty products [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | | | | 狀態: | 新提交 | | --- | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | | 公司名稱: | 醫思健康 | | | | | | | 呈交日期: | 2026年1月6日 | | | | | | | I. 法定/註冊股本變動 | | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | | 是 | | 證券代號 (如上市) | 02138 | 說明 | | | | | | | | 本月底法定/註冊股本總額： HKD 380,000 FF301 第 1 頁 共 13 頁 v 1.1.1 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 38,000,000,000 HKD 0.00001 HKD 380,000 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） | 1. 股份分 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 對 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 EC Healthcare 醫思健康 （股份代號：2138） （於開曼群島註冊成立之有限公司） 關連交易 收購目標公司已發行股本的14.6313% 收購事項 董 事 會 欣 然 宣 佈，於 二 零 二 五 年 十 二 月 三 十 一 日（交 易 時 段 後），買 方（本 公 司 間 接 全 資 附 屬 公 司）與 賣 方 訂 立 該 協 議，據 此 買 方 同 意 購 買 而 賣 方 則 同 意 出 售 銷 售 股 份，相 當 於 目 標 公 司 已 發 行 股 本 的14.6313%，總 代 價 為21,000,000 港 元，惟 須 受 該 協 議 的 條 款 及 條 件 所 規 限。 該 交 易 組 成 範 圍 更 廣 泛 的 結 算 安 排 的 一 部 分，據 此，離 任 醫 生 ...

N O T I F I C AT I O N L E T T E R 通 知 信 函 23 December 2025 Dear Non-registered holder, EC Healthcare (the "Company") Notice of Publication of Interim Report ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communication s are available on the Company's website at www.echealthcare.com and the HKEXnews website at www.hkexnews.hk. If you have elected to receive the Company's Corporate Communications in printed form, the Current Corporate Communications o ...

(Incorporated in the Cayman Islands with limited liability) EC Healthcare (the "Company") Notice of Publication of Interim Report ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communication s are available on the Company's website at www.echealthcare.com and the HKEXnews website at www.hkexnews.hk. If you have elected to receive the Company's Corporate Communications in printed form, the Current Corporate Communications of the Company is enclosed in ...

Financial Performance - Revenue for the six months ended September 30, 2025, was HK$1,930,578, a decrease of 6.4% compared to HK$2,062,897 in 2024[13] - EBITDA for the same period was HK$171,678, reflecting a decline of 30.7% from HK$247,906 in 2024[13] - Profit before tax dropped by 74.7% to HK$14,333 from HK$56,642 in the previous year[13] - Profit for the period decreased by 89.5% to HK$4,218 compared to HK$40,301 in 2024[13] - The loss attributable to owners of the Company was HK$10,312, a significant decline from a profit of HK$14,097 in 2024, marking a 173.1% change[13] - EBITDA margin decreased to 8.9% from 12.0% in the previous year, reflecting reduced operational efficiency[13] - Net profit margin fell to 0.2% from 2.0%, indicating a significant drop in profitability relative to revenue[13] - No dividend was declared for the period, compared to 1.0 HK cents per share in the previous year[13] Assets and Liabilities - Total assets increased to HK$5,319,342 as of September 30, 2025, up from HK$5,026,888 as of March 31, 2025[13] - Total liabilities rose to HK$3,104,274 from HK$2,821,892, indicating a growing debt level[13] Revenue Breakdown - Revenue from medical services decreased by 14.2% year-on-year to HK$1,084.2 million, attributed to softer market sentiment and the impact of previous disposals[50] - Revenue from aesthetic medical and beauty and wellness services increased by 7.3% to HK$676.5 million, accounting for 35.0% of total revenue, attributed to the acquisition of aesthetic medical business[104][108] - Revenue from veterinary and other services increased by 1.2% to HK$170.9 million, representing 8.9% of total revenue, primarily due to the expansion of veterinary services[105][109] Operational Initiatives - The Group's operational excellence initiatives included workforce restructuring and procurement governance enhancements to mitigate revenue pressure[35][36] - The Group expanded its insured service offerings through wellness, preventive health, and chronic-disease programs co-developed with insurance partners[27] - Enhanced package design and workplace health initiatives improved value propositions for employers, strengthening the Group's penetration across diversified industries[28] - Ecosystem integration strengthened cross-referral pathways among various service lines, enhancing service continuity and multi-service retention[32] Market Environment - The Group expects the operating environment in Hong Kong's private healthcare sector to remain challenging in the near term, but long-term fundamentals remain attractive due to rising healthcare expenditure and an aging population[71][74] - Cross-border healthcare integration within the Greater Bay Area is accelerating, supported by initiatives to enhance talent mobility and develop interoperable health-record frameworks[77] Share Options and Capital Management - The Company operates multiple share schemes, including the 2016 Share Option Scheme, which was terminated on May 29, 2023, with no options available for grant as of April 1, 2025, and September 30, 2025[166][169] - The Company has a total of 10,000,000 share options with various exercise periods, with the first set expiring in 2031[160] - The Group's capital management strategy includes selective divestment of non-core assets to enhance capital efficiency and improve asset quality[90] Future Outlook - The company remains confident in its long-term strategy and competitive position despite short-term market pressures, focusing on technology and operational transformation to capture long-term opportunities in the evolving healthcare landscape[101] - The Group is positioned to lead the next phase of market transformation in Hong Kong's healthcare sector, supported by ageing demographics and rising wellness awareness[98]

| 交易日 | 持股总数 (股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-05 | 2066.40万 | -1.30万 | -0.06% | | 2025-11-26 | 2067.70万 | -2000.0 | -0.01% | | 2025-11-21 | 2067.90万 | -2000.0 | -0.01% | | 2025-11-11 | 2068.10万 | -2000.0 | -0.01% | | 2025-11-05 | 2068.30万 | -24.90万 | -1.19% | 证券之星消息，12月5日南向资金减持1.3万股医思健康（02138.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持26.8万股。近20个交易日中，获南向资金减持的有20天，累计净减持109.2万 股。截至目前，南向资金持有医思健康（02138.HK）2066.4万股，占公司已发行普通股的1.73%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 医思健康是 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 醫思健康 | | | | | | 呈交日期: | 2025年12月3日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02138 | 說明 | | | | FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02138 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份 ...